Literature DB >> 31821885

Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.

Kareem Jamani1, Qianchuan He2, Yang Liu2, Chris Davis1, Jesse Hubbard1, Gary Schoch1, Stephanie J Lee3, Ted Gooley1, Mary E D Flowers3, Guang-Shing Cheng4.   

Abstract

Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) is often diagnosed at a late stage when lung dysfunction is severe and irreversible. Identifying patients early after transplantation may offer improved strategies for early detection that could avert the morbidity and mortality of BOS. This study aimed to determine whether a decline in lung function before and early after (days +80 to +100) allo-HCT are associated with a risk of BOS beyond 6 months post-transplantation. In a single-center cohort of 2941 allo-HCT recipients, 186 (6%) met National Institutes of Health criteria for BOS. Pretransplantation and post-transplantation day +80 spirometric parameters were analyzed as continuous variables and included in a multivariable model with other factors, including donor source, graft source, conditioning regimen, use of total body irradiation, and immunoglobulin levels. Pre-transplantation forced expiratory flow between 25% and 75% of maximum (FEF25-75), day +80 forced expiratory volume in 1 second (FEV1), and day +80 FEF25-75 had the strongest associations with increased risk of BOS. Assessment of the multivariable model showed that a decline in day +80 FEF25-75 added additional risk to the day +80 FEV1 model (P = .03), whereas FEV1 decline at day +80 added no additional risk to the day +80 FEF25-75 model (P = .645). Moreover, day +80 FEF25-75 conferred additional risk when considered with pretransplantation FEF25-75. These results suggest that day +80 FEF25-75 may be more important than FEV1 in predicting the development of BOS. This study highlights the importance of obtaining early post-transplantation pulmonary function tests for the potential risk stratification of patients at risk for BOS.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Bronchiolitis obliterans syndrome; Forced expiratory flow; Forced expiratory flow between 25% and 75% of maximum; Forced expiratory volume in 1 second; Risk factor; Spirometry

Year:  2019        PMID: 31821885      PMCID: PMC7255698          DOI: 10.1016/j.bbmt.2019.12.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  38 in total

1.  Implications of early airflow decline after myeloablative allogeneic stem cell transplantation.

Authors:  J W Chien; P J Martin; M E Flowers; W G Nichols; J G Clark
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

2.  Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Authors:  Brandon K C Au; Ted A Gooley; Philippe Armand; Min Fang; David K Madtes; Mohamed L Sorror; Michael J Boeckh; Christopher J Gibson; Hans Joachim Deeg; Rainer Storb; Frederick R Appelbaum; Jason W Chien; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-31       Impact factor: 5.742

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 4.  Targeting the small airways asthma phenotype: if we can reach it, should we treat it?

Authors:  Brian Lipworth
Journal:  Ann Allergy Asthma Immunol       Date:  2013-04       Impact factor: 6.347

5.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Authors:  Stefan O Ciurea; Mei-Jie Zhang; Andrea A Bacigalupo; Asad Bashey; Frederick R Appelbaum; Omar S Aljitawi; Philippe Armand; Joseph H Antin; Junfang Chen; Steven M Devine; Daniel H Fowler; Leo Luznik; Ryotaro Nakamura; Paul V O'Donnell; Miguel-Angel Perales; Sai Ravi Pingali; David L Porter; Marcie R Riches; Olle T H Ringdén; Vanderson Rocha; Ravi Vij; Daniel J Weisdorf; Richard E Champlin; Mary M Horowitz; Ephraim J Fuchs; Mary Eapen
Journal:  Blood       Date:  2015-06-30       Impact factor: 22.113

6.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

7.  Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.

Authors:  Vibha N Lama; Susan Murray; Jeanette A Mumford; Kevin R Flaherty; Andrew Chang; Galen B Toews; Marc Peters-Golden; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

8.  Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Authors:  Eric C Walter; Mauricio Orozco-Levi; Alba Ramirez-Sarmiento; Afonso Vigorito; Paulo V Campregher; Paul J Martin; Mary E Flowers; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-17       Impact factor: 5.742

9.  Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Guang-Shing Cheng; Angela P Campbell; Hu Xie; Zach Stednick; Cheryl Callais; Wendy M Leisenring; Janet A Englund; Jason W Chien; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-31       Impact factor: 5.742

10.  Broncho-bronchiolitis obliterans as a complication of bone marrow transplantation: a clinicopathological study of eight autopsy cases. Nagoya BMT Group.

Authors:  T Yokoi; N Hirabayashi; M Ito; Y Uno; T Tsuzuki; Y Yatabe; Y Kodera
Journal:  Virchows Arch       Date:  1997-10       Impact factor: 4.064

View more
  7 in total

1.  Noninfectious complications of hematopoietic cell transplantation.

Authors:  Kirsten M Williams
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Airway disease in hematologic malignancies.

Authors:  Ricardo J José; Burton F Dickey; Ajay Sheshadri
Journal:  Expert Rev Respir Med       Date:  2022-02-21       Impact factor: 4.300

3.  Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation.

Authors:  Yuya Kishida; Naoki Shingai; Konan Hara; Makiko Yomota; Chika Kato; Satoshi Sakai; Yasuhiro Kambara; Yuya Atsuta; Ryosuke Konuma; Atsushi Wada; Daisuke Murakami; Shiori Nakashima; Yusuke Uchibori; Daishi Onai; Atsushi Hamamura; Akihiko Nishijima; Takashi Toya; Hiroaki Shimizu; Yuho Najima; Takeshi Kobayashi; Hisashi Sakamaki; Kazuteru Ohashi; Noriko Doki
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

Review 4.  Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions.

Authors:  Allan R Glanville; Christian Benden; Anne Bergeron; Guang-Shing Cheng; Jens Gottlieb; Erika D Lease; Michael Perch; Jamie L Todd; Kirsten M Williams; Geert M Verleden
Journal:  ERJ Open Res       Date:  2022-07-25

5.  Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.

Authors:  Marcie Riches; Randy Taplitz; Carolyn M Mulroney; Muhammad Bilal Abid; Asad Bashey; Roy F Chemaly; Stefan O Ciurea; Min Chen; Christopher E Dandoy; Miguel A Diaz Perez; Brian D Friend; Ephraim Fuchs; Siddhartha Ganguly; Scott R Goldsmith; Christopher G Kanakry; Soyoung Kim; Krishna V Komanduri; Maxwell M Krem; Hillard M Lazarus; Per Ljungman; Richard Maziarz; Taiga Nishihori; Sagar S Patel; Miguel-Angel Perales; Rizwan Romee; Anurag K Singh; John Reid Wingard; Jean Yared
Journal:  Br J Haematol       Date:  2021-06-14       Impact factor: 8.615

6.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10

7.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.

Authors:  Carrie L Kitko; Joseph Pidala; Hélène M Schoemans; Anita Lawitschka; Mary E Flowers; Edward W Cowen; Eric Tkaczyk; Nosha Farhadfar; Sandeep Jain; Philipp Steven; Zhonghui K Luo; Yoko Ogawa; Michael Stern; Greg A Yanik; Geoffrey D E Cuvelier; Guang-Shing Cheng; Shernan G Holtan; Kirk R Schultz; Paul J Martin; Stephanie J Lee; Steven Z Pavletic; Daniel Wolff; Sophie Paczesny; Bruce R Blazar; Stephanie Sarantopoulos; Gerard Socie; Hildegard Greinix; Corey Cutler
Journal:  Transplant Cell Ther       Date:  2021-04-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.